|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||25.55 / 35.04|
European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.
It happened in the wake of Merck's latest drug approval.
AstraZeneca and Royal Dutch Shell will surprise investors.
GM, Bank of America and AstraZeneca are among today's active movers. Here's how to trade them.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
Shares in the biotech firm hit a record high Thursday after confirming 'exclusive' talks with Johnson & Johnson.
The biotech company has been taking a beating lately.
Akebia's vadadustat is designed to stimulate the production of red blood cells (and the oxygen-carrying molecule hemoglobin) by mimicking the body's reaction to high altitudes.
Ionis earns $25 million milestone payment
Meanwhile, Astrazeneca's shares fall as its head of oncology leaves for the smaller biotech company.
- AstraZeneca Exercises Option to License IONIS-KRAS-2.5 Rx (AZD4785)
Hundreds of millions of people worldwide suffer from chronic respiratory disease. Here's how investors can profit from the companies making strides in treating COPD.
Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.
Stocks are on track to close at fresh records on Friday as the health care sector makes a comeback after a bruising week.
Lilly's sola study did not reduce amyloid plaques in the brain, adding to the likelihood that Biogen's late-stage Alzheimer's study will prove successful.
Stocks move higher on Friday, trading at records, as the health care sector makes a comeback after a bruising week.
Stock futures move slightly higher on Friday, setting Wall Street to open at record highs after Thursday's session continued the markets' winning streak.
Here are Friday's top research calls, including upgrades for Autodesk and AstraZeneca, and downgrades for Aflac and Duluth.
AstraZeneca today announced results from a pre-specified subgroup analysis of the positive Phase III FALCON trial suggesting that treatment effects in terms of progression-free survival (PFS) were largely consistent across...
AstraZeneca reported optimistic results for its lung cancer drug Tagrisso in a trial, saying it improved progression-free survival by nearly six months.
AstraZeneca today presented data from the AURA3 trial that is supportive of TAGRISSO ® (osimertinib) potentially becoming the new standard of care for second-line treatment of patients with epidermal growth factor...
AstraZeneca and its hematology Center of Excellence, Acerta Pharma, today announced preliminary results from the Phase I/II ACE-CL-001 clinical trial of acalabrutinib in subsets of patients with two difficult-to-treat...
Stocks turn mixed Wednesday as a rally in crude oil fails to provide an across-the-board lift.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Results from the international, multicenter Child Hood Asthma Safety and Efficacy (CHASE) 3 Phase III study showed that SYMBICORT ® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.